HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study

BACKGROUND: Phase II trials showed the efficacy of anti-HER2 RC48-ADC (disitamab vedotin) for HER2-positive metastatic urothelial carcinoma (UC). This study evaluated RC48 alone verses in combination with immunotherapy for locally advanced or metastatic UC using real-world data. METHODS: This retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Meiting, Yao, Kai, Cao, Manming, Liu, Hao, Xue, Cong, Qin, Tao, Meng, Lingru, Zheng, Zhousan, Qin, Zike, Zhou, Fangjian, Liu, Zhuowei, Shi, Yanxia, An, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264489/
https://www.ncbi.nlm.nih.gov/pubmed/36897337
http://dx.doi.org/10.1007/s00262-023-03419-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264489/
https://www.ncbi.nlm.nih.gov/pubmed/36897337
http://dx.doi.org/10.1007/s00262-023-03419-1

Ejemplares similares